EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Favorable impact of zanubrutinib combined with R-CHOP regimen in MYD88-mutated new-diagnosed diffuse large B-cell lymphoma: a retrospective study with propensity score-matched analysis

Xiubin Xiao, Shunzong Yuan, Xilin Chen, Xia Liu, Ruiqing Zhao, Shihua Zhao, Yun Lu, Yi Ma, Junli Chen, Yueqi Wang, Nana Cheng, Hua Yin und 3 weitere

Cancer Immunology, Immunotherapy · 2025

DOI: 10.1007/s00262-025-04090-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2025. Verfasst von Xiubin Xiao und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100071, China. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Antineoplastic Combined Chemotherapy Protocols, Myeloid Differentiation Factor 88, Piperidines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease, with MYD88 mutations associated with poor outcomes. Enhancing standard rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy with targeted agents such as zanubrutinib, a selective Bruton tyrosine kinase inhibitor, may improve patient prognosis. This retrospective study evaluated patients with MYD88 -mutated DLBCL treated with zanubrutinib plus R-CHOP (ZR-CHOP). The ZR-CHOP group (n = 20) was compared with a propensity score-matched control group (n = 40) of patients without MYD88 mutation who received standard R-CHOP. Key outcomes included complete response rate (CRR), overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). Univariate logistic regression analyzed prognostic factors, and safety was assessed by comparing adverse events between groups. The ZR-CHOP group had a similar CRR of 75.0% compared to 67.5% in the control group and an ORR of 90.0% versus 97.5%. With a median follow-up of 26.5 months (range: 1–41), PFS and OS were analyzed. At 36 months, PFS was 61.9% in the ZR-CHOP group versus 63.8% in the control, while OS was 77.5% versus 76.7%. Among patients with MYD88 / CD79B double mutations, the CRR was 90.0%. Elevated lactate dehydrogenase levels were linked to a lower likelihood of achieving a complete response. The most common treatment-related adverse events were infections (50%) and bleeding (15%) in the ZR-CHOP group. ZR-CHOP may improve outcomes in MYD88 -mutated DLBCL, particularly in patients with MYD88 / CD79B double mutations. Although further studies are needed, zanubrutinib shows promise as a targeted therapy in this population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Large B-Cell, DiffuseAntineoplastic Combined Chemotherapy ProtocolsMyeloid Differentiation Factor 88PiperidinesPyrazolesPyrimidinesHumansMaleFemaleCyclophosphamideRetrospective StudiesVincristineMiddle AgedDoxorubicinPrednisoneMutationAgedRituximabPropensity ScoreAdultPrognosisAged, 80 and overTreatment Outcome

Stichwörter der Autor:innen

MYD88Diffuse large B-cell lymphomaPropensity score-matched analysisR-CHOP regimenZanubrutinib

Substanzen

Myeloid Differentiation Factor 88CyclophosphamideVincristineDoxorubicinPrednisonePiperidinesMYD88 protein, humanRituximabPyrazoleszanubrutinib

Autor:innen und Institutionen

  • Department of Hematology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100071, China.
  • Department of Hematology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100071, China. huangwr_301@126.com.

Zitieren

APA

Xiao, X., Yuan, S., Chen, X., Liu, X., Zhao, R., Zhao, S., Lu, Y., Ma, Y., Chen, J., Wang, Y., Cheng, N., Yin, H., Gao, H., Feng, P., & Huang, W. (2025). Favorable impact of zanubrutinib combined with R-CHOP regimen in MYD88-mutated new-diagnosed diffuse large B-cell lymphoma: a retrospective study with propensity score-matched analysis. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-025-04090-4

Vancouver

Xiao X, Yuan S, Chen X, Liu X, Zhao R, Zhao S, et al. Favorable impact of zanubrutinib combined with R-CHOP regimen in MYD88-mutated new-diagnosed diffuse large B-cell lymphoma: a retrospective study with propensity score-matched analysis. Cancer Immunology, Immunotherapy. 2025. doi:10.1007/s00262-025-04090-4

BibTeX
@article{Xiao2025,
  author = {Xiao, Xiubin and Yuan, Shunzong and Chen, Xilin and Liu, Xia and Zhao, Ruiqing and Zhao, Shihua and Lu, Yun and Ma, Yi and Chen, Junli and Wang, Yueqi and Cheng, Nana and Yin, Hua and Gao, Honghao and Feng, Pan and Huang, Wenrong},
  title = {Favorable impact of zanubrutinib combined with R-CHOP regimen in MYD88-mutated new-diagnosed diffuse large B-cell lymphoma: a retrospective study with propensity score-matched analysis},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2025},
  doi = {10.1007/s00262-025-04090-4}
}
Kostenlos starten →